Literature DB >> 19804057

Telmisartan: from lowering blood pressure to end-organ protection.

Thomas Unger1, Michael Schupp.   

Abstract

The principal aim in the treatment of patients with high blood pressure is to ensure a maximum reduction in the total risk of cardiovascular morbidity and mortality. The renin-angiotensin system plays an important role in volume homeostasis and blood pressure regulation. The angiotensin receptor blockers control high blood pressure by preventing the binding of angiotensin II to the subtype 1 receptor, which is believed to mediate most of the physiologic actions of angiotensin II relevant to the regulation of blood pressure. Telmisartan is a widely used angiotensin receptor blocker with distinct pharmacokinetic and pharmacodynamic properties. Due to its long duration of action, it compares favorably with other angiotensin receptor blockers. Latest data from clinical trials and newest research regarding telmisartan will be reviewed in this article.

Entities:  

Year:  2005        PMID: 19804057     DOI: 10.1517/14796678.1.1.7

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  2 in total

1.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

Review 2.  Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios.

Authors:  Swati Katoch; Vinesh Sharma; Vikram Patial
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.